Linker Information
General Information of This Linker
Linker ID |
LIN0KFZPW
|
|||||
---|---|---|---|---|---|---|
Linker Name |
Glu-Ala-Glu-Dpr-MDpr
|
|||||
Antibody-Linker Relation |
Cleavable
|
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
h1F6-20 MMAE DAR4 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.85% (Day 25) | Positive CD70 expression (CD70+++/++) | ||
Method Description |
To establish 786-O tumors, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 0.5 mg/kg single.
|
||||
In Vivo Model | 786-O CDX model | ||||
In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 |
hBU12-20 MMAE DAR4 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.85% (Day 25) | Positive CD70 expression (CD70+++/++) | ||
Method Description |
To establish 786-O tumors, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 0.5 mg/kg single.
|
||||
In Vivo Model | 786-O CDX model | ||||
In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 |
h1F6-20 MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.79% (Day 25) | Positive CD70 expression (CD70+++/++) | ||
Method Description |
To establish 786-O tumors, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 0.5 mg/kg single.
|
||||
In Vivo Model | 786-O CDX model | ||||
In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
7.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
9.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
In Vitro Model | Clear cell renal cell carcinoma | Caki-1 cells | CVCL_0234 |
hBU12-20 MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.79% (Day 25) | Positive CD70 expression (CD70+++/++) | ||
Method Description |
To establish 786-O tumors, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 0.5 mg/kg single.
|
||||
In Vivo Model | 786-O CDX model | ||||
In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
7.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
9.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
In Vitro Model | Clear cell renal cell carcinoma | Caki-1 cells | CVCL_0234 |
h1F6-18 MMAE [Investigative]
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
8.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
18.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
In Vitro Model | Clear cell renal cell carcinoma | Caki-1 cells | CVCL_0234 |
hBU12-18 MMAE [Investigative]
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
8.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
18.00 ng/mL
|
Positive CD70 expression (CD70+++/++) | ||
Method Description |
Log phase cultures of cells were collected and cells plated at seeding densities ranging from 500 - 10,000 cells/well according to pre-determined conditions.After incubating 24 hours to allow surface protein reconstitution, serial dilutions of test conjugates were added and cultures incubated further for 4 days.
|
||||
In Vitro Model | Clear cell renal cell carcinoma | Caki-1 cells | CVCL_0234 |
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.